Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

ErbB1 and ErbB2 receptors are well-characterized targets for anticancer drugs, but the clinical relevance of the related ErbB4 receptor is unknown. Here, we have assessed the clinical significance of the proteolytically cleavable ErbB4 isoforms in breast cancer patients and investigated their functions in vitro. The expression of transcripts encoding the cleavable ErbB4 isoforms associated with estrogen receptor-alpha (ER) expression (P < 0.001) and a high histologic grade of differentiation (P </= 0.002) in real-time reverse transcription-PCR analysis of 62 breast cancer samples. Despite high ErbB4 mRNA expression levels in a subset of samples, ErbB4 gene amplification was not observed. High ErbB4 protein expression levels, as assessed by immunohistochemistry, associated with a favorable outcome in ER-positive cases from a series of 458 breast cancer patients (P = 0.01), whereas no association between ErbB4 expression and survival was found among women with ER-negative cancer (P = 0.86). However, nuclear ErbB4 immunoreactivity was associated with poor survival as compared with women whose cancer had membranous ErbB4 staining (P = 0.04). In vitro, overexpression of a cleavable ErbB4 isoform in ER-positive breast cancer cells resulted in translocation of a proteolytically released intracellular ErbB4 receptor fragment into the nucleus, as well as, enhanced proliferation, anchorage-independent growth, and estrogen response element-mediated transcriptional activity. These results suggest that the association of ErbB4 expression with clinical outcome is dependent on the subcellular localization of ErbB4 and that a proteinase-cleavable ErbB4 isoform promotes growth of ER-positive breast cancer and enhances ER-mediated gene transcription.

[1]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[2]  Jorma Isola,et al.  Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[4]  N. Navin,et al.  WW Domain-containing Protein YAP Associates with ErbB-4 and Acts as a Co-transcriptional Activator for the Carboxyl-terminal Fragment of ErbB-4 That Translocates to the Nucleus* , 2003, Journal of Biological Chemistry.

[5]  J. Isola,et al.  Haplo-insufficiency of BRCA1 in sporadic breast cancer. , 2003, Cancer research.

[6]  W. Gullick.  c‐erbB‐4/HER4: friend or foe? , 2003, The Journal of pathology.

[7]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[8]  Xiaoming Deng,et al.  Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. , 2003, Cancer research.

[9]  B. Angus,et al.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 , 2003, Journal of clinical pathology.

[10]  Mikael Lundin,et al.  Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[12]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[13]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[14]  R. Allibone,et al.  Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma , 2001, Genes, chromosomes & cancer.

[15]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[16]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[17]  G. Carpenter,et al.  Heregulin-dependent Trafficking and Cleavage of ErbB-4* , 2000, The Journal of Biological Chemistry.

[18]  F. Révillion,et al.  Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[20]  J. Määttä,et al.  Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. , 2000, Trends in cardiovascular medicine.

[21]  M. Jäättelä,et al.  Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF‐7 breast carcinoma cells , 2000, International journal of cancer.

[22]  J. Buxbaum,et al.  Tumor Necrosis Factor-α-converting Enzyme Is Required for Cleavage of erbB4/HER4* , 2000, The Journal of Biological Chemistry.

[23]  M. Klagsbrun,et al.  A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.

[24]  D. Barnes,et al.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.

[25]  I. Ellis,et al.  c-erbB-4 protein expression in human breast cancer , 2000, British Journal of Cancer.

[26]  Careen K. Tang,et al.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. , 1999, Cancer research.

[27]  M. Klagsbrun,et al.  Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase , 1999, Oncogene.

[28]  I. Ellis,et al.  c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer , 1998, Oncogene.

[29]  M. Klagsbrun,et al.  A Novel Juxtamembrane Domain Isoform of HER4/ErbB4 , 1997, The Journal of Biological Chemistry.

[30]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[31]  R. Lupu,et al.  Involvement of Heregulin-β2 in the Acquisition of the Hormone-independent Phenotype of Breast Cancer Cells , 1996 .

[32]  Y. Yarden,et al.  An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.

[33]  Y. Yarden,et al.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. , 1996, The American journal of pathology.

[34]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[35]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[36]  M. Kraus,et al.  Localization of the human HER4/erbB-4 gene to chromosome 2. , 1995, Oncogene.

[37]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[38]  R. Derynck,et al.  Mapping of transforming growth factor alpha gene on human chromosome 2 close to the breakpoint of the Burkitt's lymphoma t(2;8) variant translocation. , 1985, Cancer research.

[39]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[40]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF-alpha in tumors. , 2003, The EMBO journal.

[41]  L. Mei,et al.  Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. , 2002, The Journal of biological chemistry.

[42]  Sandip K. Mishra,et al.  Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor , 2000, Nature Cell Biology.

[43]  R. Lupu,et al.  Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. , 1996, Cancer research.